Mirum Pharmaceuticals Statistics
Share Statistics
Mirum Pharmaceuticals has 48.00M shares outstanding. The number of shares has increased by 2.98% in one year.
| Shares Outstanding | 48.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.62% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 38.27M |
| Failed to Deliver (FTD) Shares | 313 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 6.84M, so 14.26% of the outstanding shares have been sold short.
| Short Interest | 6.84M |
| Short % of Shares Out | 14.26% |
| Short % of Float | 17.88% |
| Short Ratio (days to cover) | 16.11 |
Valuation Ratios
The PE ratio is -7.39 and the forward PE ratio is -48.6.
| PE Ratio | -7.39 |
| Forward PE | -48.6 |
| PS Ratio | 6.48 |
| Forward PS | 4 |
| PB Ratio | 4.85 |
| P/FCF Ratio | -13.26 |
| PEG Ratio | n/a |
Enterprise Valuation
Mirum Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.23B.
| EV / Earnings | -7.52 |
| EV / Sales | 6.59 |
| EV / EBITDA | -9 |
| EV / EBIT | -11.26 |
| EV / FCF | -13.49 |
Financial Position
The company has a current ratio of 4.45, with a Debt / Equity ratio of 1.23.
| Current Ratio | 4.45 |
| Quick Ratio | 4.19 |
| Debt / Equity | 1.23 |
| Total Debt / Capitalization | 55.2 |
| Cash Flow / Debt | -0.23 |
| Interest Coverage | -7.23 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on capital (ROIC) is -19.72%.
| Return on Equity (ROE) | -0.66% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -19.72% |
| Revenue Per Employee | 599.27K |
| Profits Per Employee | -525.45K |
| Employee Count | 311 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.11 |
Taxes
| Income Tax | 991.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 48.21% in the last 52 weeks. The beta is 1.16, so Mirum Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | 48.21% |
| 50-Day Moving Average | 42.4 |
| 200-Day Moving Average | 35.68 |
| Relative Strength Index (RSI) | 52.45 |
| Average Volume (20 Days) | 357.26K |
Income Statement
In the last 12 months, Mirum Pharmaceuticals had revenue of 186.37M and earned -163.41M in profits. Earnings per share was -4.
| Revenue | 186.37M |
| Gross Profit | 139.34M |
| Operating Income | -109.15M |
| Net Income | -163.41M |
| EBITDA | -136.49M |
| EBIT | -109.15M |
| Earnings Per Share (EPS) | -4 |
Balance Sheet
The company has 286.33M in cash and 308.14M in debt, giving a net cash position of -21.82M.
| Cash & Cash Equivalents | 286.33M |
| Total Debt | 308.14M |
| Net Cash | -21.82M |
| Retained Earnings | -556.24M |
| Total Assets | 667.89M |
| Working Capital | 270.88M |
Cash Flow
In the last 12 months, operating cash flow was -70.94M and capital expenditures -20.11M, giving a free cash flow of -91.05M.
| Operating Cash Flow | -70.94M |
| Capital Expenditures | -20.11M |
| Free Cash Flow | -91.05M |
| FCF Per Share | -2.23 |
Margins
Gross margin is 7.48K%, with operating and profit margins of -5.86K% and -8.77K%.
| Gross Margin | 7.48K% |
| Operating Margin | -5.86K% |
| Pretax Margin | -8.71K% |
| Profit Margin | -8.77K% |
| EBITDA Margin | -73.23% |
| EBIT Margin | -58.57% |
| FCF Margin | -48.85% |
Dividends & Yields
MIRM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.35% |
| FCF Yield | -4.44% |
Analyst Forecast
The average price target for MIRM is $63, which is 47.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $63 |
| Price Target Difference | 47.3% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 2.02 |
| Piotroski F-Score | 2 |